Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SK Biopharmaceuticals Co. Ltd.

www.skbp.com/eng

Latest From SK Biopharmaceuticals Co. Ltd.

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

South Korea Clinical Trials

Key Words For Korean Pharma In 2010s: Novelty, Open Innovation, Global Markets

From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.

South Korea Business Strategies

Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact

The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.

South Korea Gene Therapy

Major Milestone For SK Biopharm As Anti-Epileptic Gets US Approval

SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.

Approvals Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • SK Biopharmaceuticals Co. Ltd.
  • Senior Management
  • Jeong Woo Cho, PhD, Pres. & CEO
    Jiyoung Jung, VP, CFO
    Kiho Lee, PhD, VP, R&D
  • Contact Info
  • SK Biopharmaceuticals Co. Ltd.
    Pangyo,
    South Korea
UsernamePublicRestriction

Register